Released August 19, 2019 | SUGAR LAND
en
Industrial Info is tracking 115 capital construction projects to build cannabis cultivation, processing and production facilities. The notoriously secretive and convoluted cannabis sector has this $3 billion investment scattered across the globe, with far more to follow, as it continues its explosive growth. See map below for project locations. Used in the healing arts for more than 6,000 years, cannabis is staking its claim of legitimacy.
The plant, or more correctly, its derivatives, called cannabinoids, are making their way into scores of products. The two major cannabinoids found in the cannabis plant are cannabidiol (CBD)--considered a "healing component" and tetrahydrocannabinol (THC )--the principal psychoactive ingredient. CBD is expected to contain no more than .3% of THC. A number of conditions being studied for treatment by CBD includes epilepsy, arthritis, schizophrenia and oncologic side effects.
The legalization laws and licensing procedures are still murky, with wide variances from location to location. The entire cannabis process flow is still being defined and developed--much to the joy of traditional Pharma-Bio Industry suppliers. Because there is no precedent, nor long-term established relationships, this cash intense sector has become a very attractive target.
The plant, or more correctly, its derivatives, called cannabinoids, are making their way into scores of products. The two major cannabinoids found in the cannabis plant are cannabidiol (CBD)--considered a "healing component" and tetrahydrocannabinol (THC )--the principal psychoactive ingredient. CBD is expected to contain no more than .3% of THC. A number of conditions being studied for treatment by CBD includes epilepsy, arthritis, schizophrenia and oncologic side effects.
The legalization laws and licensing procedures are still murky, with wide variances from location to location. The entire cannabis process flow is still being defined and developed--much to the joy of traditional Pharma-Bio Industry suppliers. Because there is no precedent, nor long-term established relationships, this cash intense sector has become a very attractive target.
